References
[1] Prashant Pradhan, Ashutosh Kumar Pandey, Akhilesh Mishra, Parul
Gupta1, Praveen Kumar Tripathi1, Manoj Balakrishnan Menon1, James
Gomes1, Perumal Vivekanandan and Bishwajit Kundu, Uncanny similarity of
unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag,
bioRxiv, doi: https://doi.org/10.1101/2020.01.30.927871.
[2] Jasper Fuk-Woo Chan, Kin-Hang Kok, Zheng Zhu, Hin Chu, Kelvin
Kai-Wang To, Shuofeng Yuan & Kwok-Yung Yuen, Genomic characterization
of the 2019 novel human pathogenic coronavirus isolated from a patient
with atypical pneumonia after visiting Wuhan, Emerging Microbes &
Infections, 2020.
[3] Berend Jan Bosch, Ruurd van der Zee, Cornelis A. M. de Haan, and
Peter J. M. Rottier, The Coronavirus Spike Protein Is a Class I Virus
Fusion Protein: Structural and Functional Characterization of the Fusion
Core Complex, JOURNAL OF VIROLOGY, Aug. 2003, p. 8801–8811 Vol. 77, No.
16.
[4] R.Savino, LCiapponi, A.Lahm1, A.Demartis, A.Cabibbo, C.Toniatti,
PRDelmastro2, S.Altamura and G.Ciliberto3, Rational design of a receptor
super-antagonist of human interleukin-6, The EMBO Journal vol.13 no.24
pp.5863-5870, 1994.
[5] Ravinder Reddy Gaddam, Stephen Chambers and Madhav Bhatia, ACE
and ACE2 in Inflammation: A Tale of Two Enzymes, Inflammation & Allergy
- Drug Targets, 2014.
[6] Hai-Yan Jin, Bei Song, Gavin Y. Oudit, Sandra T. Davidge,
Hui-Min Yu, Yan-Yan Jiang,
Ping-Jin Gao1,2, Ding-Liang Zhu1,2, Guang Ning1, Zamaneh Kassiri3, Josef
M. Penninger6, Jiu- Chang Zhong, ACE2 Deficiency Enhances Angiotensin
II-Mediated Aortic Profilin-1 Expression, Inflammation and Peroxynitrite
Production, PLoS ONE, June 2012, Volume 7, Issue 6.
[7]
Ruiz-Ortega
M, Esteban
V, Rupérez
M, Sánchez-López
E, Rodríguez-Vita
J, Carvajal
G, Egido
J, Renal and vascular hypertension-induced inflammation: role of
angiotensin II. ,
Curr Opin Nephrol
Hypertens. 2006 Mar;15(2):159-66.
[8] Tianxi Cai, ScD; Yichi Zhang, PhD; Yuk-Lam Ho, MPH; Nicholas
Link, BA; Jiehuan Sun, PhD; Jie Huang, MS; Tianrun A. Cai, MD; Scott
Damrauer, MD;, Association of Interleukin 6 Receptor Variant With
Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking
Therapy A Phenome-Wide Association Study, JAMACardiology.
[9] Mohammed A.R. Chamsi-Pasha, MD1, Zhili Shao, MD PhD2, and W. H.
Wilson Tang, MD2, Angiotensin-Converting Enzyme 2 as a Therapeutic
Target for Heart Failure, Curr Heart Fail Rep, 2015.
[10]
David
Gurwitz, Angiotensin receptor blockers as tentative SARS‐CoV‐2
therapeutics,2020, https://doi.org/10.1002/ddr.21656.
[11] Julio Caballero, Considerations for Docking of Selective
Angiotensin-Converting Enzyme Inhibitors, molecules, 2020, 25, 295.
[12] Lanying Du, Yuxian He, Yusen Zhou, Shuwen Liu, Bo-Jian Zheng∥,
and Shibo Jiang, The spike protein of SARS-CoV — a target for vaccine
and therapeutic development, Nat Rev Microbiol. 2009 March ; 7(3):
226–236.
[13] Haibo Zhang, Josef M. Penninger, Yimin Li, Nanshan Zhong and
Arthur S. Slutsky, Angiotensin‑converting enzyme 2 (ACE2) as a
SARS‑CoV‑2 receptor: molecular mechanisms and potential therapeutic
target, Intensive Care Med, 2020.
[14]Yun Chen et al., Biochemical and Biophysical Research
Communications, 2020.
[15] Vaidya KA, Kadam AV and Nema V, Anti-Retroviral Drugs for HIV:
Old and New, Austin Journal of HIV/AIDS Research, 2016.
[16] Álvaro H. Borges,1 Jemma L. O’Connor,2 Andrew N. Phillips,2
Frederikke F. Rönsholt,3 Sarah Pett,2,4,5 Michael J. Vjecha,6 Martyn A.
French,7,8 and Jens D. Lundgren1; for the INSIGHT SMART and ESPRIT Study
Groups and the SILCAAT Scientific Committee, Factors Associated With
Plasma IL-6 Levels During HIV Infection, JID 2015:212.
[17] Faustina Nkechi Osuji1, Charles Chinedu Onyenekwe, Joseph Ebere
Ahaneku and Nkiruka Rose Ukibe, The effects of highly active
antiretroviral therapy on the serum levels of proinflammatory and
anti-inflammatory cytokines in HIV infected subjects, Osuji et al.
Journal of Biomedical Science (2018) 25:88.
[18] Christine Rogez-Kreuz1, Benjamin Mane´ glier1, Marc Martin1,
Nathalie Dereuddre-Bosquet, Jacques Martal, Dominique Dormont and Pascal
Clayette, Involvement of IL-6 in the anti-human immunodeficiency virus
activity of IFN-s in human macrophages, International Immunology, Vol.
17, No. 8, pp. 1047–1057.
[19] By Rachel A. Burke, Pharm.D., BCACP; and Nicole D. White,
Pharm.D., Biologic Disease-Modifying Antirheumatic Drugs, PSAP 2014.
[20] H. Haibel and C. Specker, Disease-modifying anti-rheumatic
drugs in rheumatoid arthritis and ankylosing spondylitis, CLINICAL AND
EXPERIMENTAL RHEUMATOLOGY 2009.
[21]Yousuke Furuta et al., T-705 ( favipiravir) and related
compounds, Antiviral Research, 82(2009) 95-102.
[22]
Jasvinder
A Singh,
Alomgir
Hossain,
Elizabeth
Tanjong Ghogomu,
Ahmed
Kotb, Robin
ChristensenAmy
S Mudano,
Lara
J Maxwell,
Nipam
P Shah,
Peter
Tugwell,
George
A Wells, Biologics or tofacitinib for rheumatoid arthritis in
incomplete responders to methotrexate or other traditional
disease‐modifying anti‐rheumatic drugs: a systematic review and network
meta‐analysis, https://doi.org/10.1002/14651858.CD012183.
[23] WHO Model Formulary 2008.
,